Nanozyme targets hypoxic lesions to enhance radiosensitivity in nasopharyngeal carcinoma
A collaborative study published on January 21 in Nature Communications presents a novel strategy to improve the effectiveness ...
Earnings call transcript: Bio-Rad Q4 2024 results miss forecasts
Bio-Rad Laboratories Inc (NYSE:BIO). reported its fourth-quarter 2024 earnings, revealing a slight miss on revenue expectations, with net sales of $668 million compared to a forecast of $681.29 ...